IONpath Revenue and Competitors

Location

$18M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • IONpath's estimated annual revenue is currently $4M per year.(i)
  • IONpath's estimated revenue per employee is $77,500
  • IONpath's total funding is $18M.

Employee Data

  • IONpath has 51 Employees.(i)
  • IONpath grew their employee count by 38% last year.

IONpath's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEO Reveal Email/Phone
3
VP EngineeringReveal Email/Phone
4
VP PathologyReveal Email/Phone
5
Director Data Science / Machine LearningReveal Email/Phone
6
Chief Commercial Officer (CCO)Reveal Email/Phone
7
Director Product DevelopmentReveal Email/Phone
8
Senior Business DirectorReveal Email/Phone
9
Director Scientific OperationsReveal Email/Phone
10
Director Pathology & Spatial Proteomics ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is IONpath?

IONpathâ„¢ is a venture-backed, commercial-stage company, founded by Stanford researchers out of the lab of Dr. Garry Nolan, focused on revolutionizing pathology with Multiplexed Ion Beam Imaging (MIBI) technology. MIBI is a multiplexed imaging platform with unmatched resolution, sensitivity, and throughput.

keywords:N/A

$18M

Total Funding

51

Number of Employees

$4M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

IONpath News

2022-03-22 - Fluidigm Appeal in IonPath Patent Infringement Battle ...

NEW YORK – A federal court has dismissed an appeal by Fluidigm in an ongoing patent infringement lawsuit with IonPath.

2021-08-26 - Ionpath Expands Biopharmaceutical Partnerships Program to Rapidly Deliver Novel Insights Utilizing the Company's High-Definition Spatial Proteomics Platform

MENLO PARK, Calif., Aug. 26, 2021 /PRNewswire/ -- Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplex ...

2020-09-28 - IONpath Raises $18M in Series B Financing

IONpath, Inc., a Menlo Park, Calif.-based developer of high-definition spatial proteomics, closed a $18m Series B financing. The round was led by Samsara BioCapital, with participation from new investor Bruker Corporation, and existing major investors Genoa Ventures, ND Capital, Paladin Partner ...

2020-09-24 - IONpath Closes $18 Million Series B Financing to Advance Precision Medicine

MENLO PARK, Calif., Sept. 24, 2020 /PRNewswire/ -- IONpath, Inc., the leader in high-definition spatial proteomics, today announced the close of a $18 million Series B financing led by Samsara BioCapital, and included participation from new investor Bruker Corporation, a global leader in mass ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.9M516%N/A
#2
$9.8M52-7%N/A
#3
$7.5M5347%N/A
#4
$6.5M53-2%$8.9M
#5
$16M554%N/A